A map of pharmaceutical sciences

Ask a formulation scientist and a pharmacovigilance officer what they do all day and you'd struggle to guess they work in the same industry. One is choosing a coating polymer so a tablet survives stomach acid; the other is reading adverse-event reports seven years after that tablet shipped. "Pharmaceutical sciences" is not one field — it's roughly thirteen, loosely federated under a name that promises more coherence than the field actually has.

I'm using this page as the index for the rest of this pillar. It lists the domains, with a one-line sense of what each one actually does, and links out wherever I've written the note — which right now means one branch, pharmacokinetics and pharmacodynamics, because that's the corner I've spent the most time in while deciding whether to go do a PhD in it. Everything else on this page is scaffolding: a name and a placeholder, not a claim that I understand it. I'll keep adding branches and links as I go deeper into other domains, so treat this as dated, not finished.

Medicinal chemistry#

Designing and synthesising the drug molecule itself — structure-activity relationships, computational molecular modelling, fragment-based drug discovery, prodrug design. The "what molecule do we even make" layer, upstream of everything else here.

Pharmacology#

How a drug interacts with the body at the mechanism level — receptor binding, signalling cascades, systems-level network behaviour. Includes systems pharmacology, which is where this domain starts overlapping with PK/PD below: instead of one target, one effect, it treats a drug's effect as a perturbation to a whole biological network.

Pharmaceutics and drug delivery#

Turning a molecule into a product a patient can actually take: tablet and capsule design, controlled-release systems, nanoparticle and targeted delivery, transdermal and pulmonary routes. Biopharmaceutics — how the product's physical form governs how much drug actually reaches the bloodstream — sits here too, and connects directly into bioavailability work below.

Pharmacokinetics and pharmacodynamics (PK/PD)#

What the body does to a drug, and what the drug does to the body, expressed quantitatively. This is the branch I've actually written up:

• ADME — absorption, distribution, metabolism, excretion: the four-stage obstacle course every drug runs before it can do anything useful.
• Population pharmacokinetics — why the same dose behaves differently across a real, diverse population, and how to model that statistically.
• Nonlinear PK modelling — what happens once a drug saturates the systems that clear it, and the maths that stops working when it does.
• Drug-drug interactions — how one drug changes what another drug does, usually through a shared liver enzyme.
• PBPK modelling — building a virtual human body, organ by organ, and simulating a drug's path through it instead of fitting an abstract compartment model.
• Pharmacometrics — the integrating discipline that uses all of the above to answer one question: what dose, for which patient, at what stage of disease.
• Bioavailability and bioequivalence — the science that decides whether a generic tablet is allowed to be called the same drug as the branded one.
• Therapeutic drug monitoring — measuring a drug's level in an actual patient's blood and adjusting the dose in real time, for the drugs where guessing by bodyweight isn't safe enough.

Pharmacognosy and natural products#

Medicines from natural sources — phytochemistry, ethnopharmacology, marine and microbial natural products, traditional medicine systems. Not a domain I've looked into yet.

Pharmaceutical biotechnology#

Biologics: recombinant proteins, monoclonal antibodies, gene and cell therapy, mRNA, biosimilars, vaccine development, and the upstream/downstream bioprocessing that manufactures them. This is where I'd expect the most overlap with the bioprocess-eng pillar once I write it up — not started here yet.

Toxicology#

Preclinical safety assessment, genotoxicity, organ-specific and reproductive toxicology, regulatory toxicology, risk assessment. Not started.

Clinical pharmacy#

Patient-facing drug therapy management — oncology, infectious disease, paediatric, geriatric, and critical care pharmacy practice. Not started.

Pharmaceutical analysis and quality#

The measurement layer: chromatography and spectroscopy, bioanalytical chemistry, stability and dissolution testing, quality control, GLP. Not started, though it borders GMP territory I already know from six years at Leucine — likely an early candidate for expansion.

Regulatory affairs and drug policy#

Approval pathways (FDA, EMA, ICH), GMP, pharmacovigilance, IP and patent law, orphan drug and generic drug policy. Also close to what I already know from work — another likely early expansion.

Pharmaceutical microbiology#

Sterility and endotoxin testing, microbial contamination control, aseptic processing, antibiotic and antiviral drug research. Not started.

Pharmacoepidemiology and pharmacoeconomics#

Population-level drug use, real-world evidence, adverse drug reaction surveillance, cost-effectiveness and health economics. Not started.

Social and behavioural pharmacy#

Medication adherence, patient communication, health literacy, access to medicines. Not started.